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Erythomycins/lincosamind/macrolides (49%), Penicillins
(39%), Cephalosporin (9%) and Sulfonamides/Trimetho-
prim (3%). Out of 6 factors explored, only pediatricians
were more likely to prescribe antibiotics for acute bron-
chitis than non-pediatricians (OR = 12.78; 95% CI,
1.42–115.19). CONCLUSIONS: Our study conﬁrms the
dramatic decrease in potentially inappropriate antibiotic
prescribing for children diagnosed with common colds
and URIs. The rate of potentially inappropriate antibiotic
prescribing remained high (79%) for children diagnosed
with bronchitis with the highest rates observed for chil-
dren seeking care from a pediatrician. More than half of
antibiotic classes prescribed for bronchitis were consid-
ered to be ineffective for underlining pathogens in cases
of bacterial bronchitis complications.
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OBJECTIVES: The objective of this health technology
assessment (HTA) commissioned by the German Agency
for HTA/ German Federal Ministry of Health was to
establish an interdisciplinary expert network, to system-
atically review the evidence on effectiveness and cost-
effectiveness of initial antiviral combination therapy for
chronic hepatitis C (CHC) and to apply these data in the
context of the German health care system. METHODS:
A systematic literature review was conducted and study
quality/transferability to the German context were
assessed using standard instruments of the German
Agency for HTA. A decision-analytic Markov model was
developed including pooled short-term outcomes (sus-
tained virological response [SVR] and respective pooled
relative risks) from a recently published Cochrane
Review, single RCTs, utilities from a large German
quality-of-life survey in CHC patients (n = 428), and
German cost data. The model was used to determine
long-term morbidity, life expectancy, and lifetime costs of
different treatment strategies using the societal perspec-
tive. One- and multi-way sensitivity analyses were per-
formed. RESULTS: International clinical studies indicate
that combination therapy with pegylated interferon and
ribavirin (PCOM) achieves highest SVR (54–61%), fol-
lowed by standard combination therapy with interferon
and ribavirin (SCOM) with 37–54%, and interferon
monotherapy (MONO) with 11–21%. Based on interna-
tional cost-effectiveness studies, SCOM is “cost-effective”
compared to MONO. Our decision analysis conﬁrmed
these ﬁndings for the German health care context. No
published articles were available for assessing the cost-
effectiveness of PCOM. Based on our decision analysis,
PCOM dominated SCOM, and its discounted incremen-
tal cost-effectiveness ratio compared to MONO was
€8,200 per quality-adjusted life year. These results were
robust in sensitivity analyses. CONCLUSIONS: This
HTA suggests that initial combination therapy should
prolong life, improve quality-adjusted life expectancy,
and be cost-effective in patients with chronic hepatitis C.
The combination of pegylated interferon and ribavirin is
currently the most effective and efﬁcient antiviral treat-
ment for CHC.
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OBJECTIVES: High coverage is crucial for the success of
vaccination strategies. We investigate the effect of differ-
ent coverage levels of varicella vaccination in Germany
on the possible elimination of varicella, clinical effective-
ness (measured as percentage of preventable varicella
cases prevented), possibility of age-shifts, and economic
outcomes. METHODS: Using an established, age-
structured, decision-analytic model named EVITA 
(Economic Varicella VaccInation Tool for Analysis), 
we analyze the impact of vaccinating children aged 15
months against varicella-zoster-virus. Main assumptions
are: efﬁcacy 86%, costs discounted by 5%, analytic time
horizon 30 yrs. Coverage levels are varied from 0% to
100%. RESULTS: For coverage levels above 75%, vari-
cella can be eliminated within 26.5 years (at 75%), 18
years (at 85%) and 14.5 years (at 100%). At coverage
levels below 30% clinical effectiveness is smaller than the
respective coverage levels, from 40% to 70% clinical
effectiveness is higher than coverage showing the strong
effect of herd immunity. Above 70% clinical effectiveness
remains nearly constant due to the elimination. Because
vaccination is very effective in reducing the number of
cases in young children, the relative proportion of vari-
cella cases of adolescents and adults increases. However,
the total number of cases declines in all age groups for
coverage levels above 50%, i.e. no age-shift occurs. Costs
rise linear with coverage, savings rise even steeper until
70% coverage and remain constant for higher coverage
levels. Therefore, net savings are greatest at coverage
levels of about 70%. Beneﬁt-cost-ratios rise up to cover-
age levels of 70% and fall for coverage higher than 80%.
All beneﬁt-cost-ratios are above 1 showing that net
savings occur from both perspectives the payers’ and the
societal. CONCLUSIONS: Epidemiological considera-
tions favor coverage levels of more than 75% to elimi-
nate varicella and to ensure that no age-shift occurs. From
576 Abstracts
an economic perspective, vaccination with these coverage
levels is cost-beneﬁcial.
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OBJECTIVES: To determine the annual incidence of
severe sepsis in the Netherlands by performing a point-
prevalence survey in multiple intensive care units.
METHODS: ICU’s were invited to participate in a one-
day survey and monitor patients during the ﬁrst 24 hours
of their stay, if they were admitted with a proven/
suspected infection. Patient-speciﬁc questionnaires cap-
tured demographic and clinical information, presence of
Systemic Inﬂammatory Response Syndrome (SIRS), and
the functional status of seven organ systems. The annual
national incidence was calculated from the results of the
survey following two approaches: 1) by multiplying the
survey incidence (patients/day) with the number of days
per year, corrected for the fact that the survey was held
on a weekday, and 2) by using the relation P = I ·D (P for
prevalence, I for incidence and D for duration of stay) in
which P was known from the survey and D was estimated
as the geometrical mean of duration-to-date. RESULTS:
Forty-seven ICU’s participated (in 43 general and 4 
university hospitals), representing 42% of the national
admission capacity. During the study-period, 18 patients
meeting criteria for severe sepsis were newly admitted,
and another 116 patients with severe sepsis were already
present. According to the ﬁrst calculation method, the
annual incidence of severe sepsis was 13,137 ± 2,821
patients, whereas the second method, with an estimated
D of 13.3 ± 1.1 days, lead to a calculated incidence of
8,643 ± 929 patients/year. CONCLUSIONS: Using 
the results from a point-prevalence survey, different
approaches lead to different outcomes. Both approaches
hold advantages and disadvantages. The second method
is considered superior because it is based on a larger 
population and is less sensitive to daily variations.
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OBJECTIVES: HPV DNA has been detected in up to
99.7% of all cervical cancers, and infection with 2 types
(HPV-16, 18) accounts for more than 50% of cases. 
We developed a computer-based Markov model of the
natural history of HPV infection and cervical carcino-
genesis to project the impact of a prophylactic vaccine
against HPV 16/18 infection on the age-speciﬁc incidence
and lifetime risk of invasive cervical cancer, precursor 
cervical lesions, and type-speciﬁc infection with HPV.
METHODS: A comprehensive literature review was con-
ducted to deﬁne plausible ranges for parameter values and
the model was then calibrated to the best available 
population-based data. We explored the impact of alter-
native assumptions about vaccine efﬁcacy, waning immu-
nity, and competing risks associated with non-16/18 HPV
types in vaccinated women. RESULTS: The model pre-
dicted a peak age-speciﬁc cancer incidence of 90 per
100,000 in the 6th decade, a lifetime cancer risk of 3.7%,
and a reproducible representation of type-speciﬁc HPV
within precancerous lesions and cervical cancer. A vaccine
that prevented 98% of persistent HPV 16/18 was asso-
ciated with an approximate equivalent reduction in
16/18-associated cancer and a 51% reduction in total cer-
vical cancer. A vaccine that prevented 75% of persistent
HPV 16/18 was associated with a 70% to 83% reduction
in 16/18-associated cancer cases. Several modeling
assumptions were identiﬁed that resulted in ampliﬁcation
or blunting of the vaccine’s effect on outcomes—however,
when the vaccine was either very ineffective (e.g., less
than 20% efﬁcacy) or very effective (e.g., more than 80%
efﬁcacy), the differences in projected outcomes associated
with these were minimal. CONCLUSIONS: A prophy-
lactic vaccine that prevents persistent HPV 16/18 
infection can be expected to signiﬁcantly reduce HPV-
16/18-associated LSIL, HSIL and cervical cancer.
OTHER DISEASES/DISORDERS—Economic
Outcomes
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OBJECTIVES: It was hypothesised that the total cost of
managing a bleed in haemophilia patients with high titre,
high responding inhibitors (from initiation of the bleed to
resolution) by FEIBA or NovoSeven would be compara-
ble due to a higher ﬁrst-line efﬁcacy despite the greater
cost of NovoSeven. METHODS: Direct costs were 
compared from the perspective of the National Health
Service. Resource utilisation was based on a retrospective
analysis of bleeding episodes treated in Slovakia during
the period 1990–2001. Clinical outcomes were based on
a review of the international literature, data obtained
from the retrospective analysis and the consensus of an
expert panel of ﬁve Slovakian. A decision analytic eco-
